Prostate Cancer Therapeutics Market Scope And Analysis

  • Report Code : TIPRE00003423
  • Category : Pharmaceuticals
  • No. of Pages : 150
Buy Now

Prostate Cancer Therapeutics Market Scope and Analysis Report by 2030

Buy Now

Prostate Cancer Therapeutics Market Report Prostate Cancer Therapeutics Market Size and Share Prostate Cancer Therapeutics Market Scope and Analysis

Prostate Cancer Therapeutics Market Report Scope

Report Attribute Details
Market size in 2022 US$ 14,767.73 Million
Market Size by 2030 US$ 28,425.27 Million
Global CAGR (2022 - 2030) 8.5%
Historical Data 2020-2022
Forecast period 2022-2030
Segments Covered By Therapy Type
  • Hormonal Therapy
  • Chemotherapy
  • Targeted Therapy
  • Immunotherapy
By End User
  • Hospitals
  • Specialty Clinics
Regions and Countries Covered North America
  • US
  • Canada
  • Mexico
Europe
  • UK
  • Germany
  • France
  • Russia
  • Italy
  • Rest of Europe
Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • Rest of Asia-Pacific
South and Central America
  • Brazil
  • Argentina
  • Rest of South and Central America
Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Rest of Middle East and Africa
Market leaders and key company profiles
  • Astella Pharma Inc
  • Johnson Johnson Services Inc
  • Eli Lilly and Company
  • Bayer AG
  • Sanofi
  • Merck KGaA
  • AstraZeneca
  • Novartis AG
  • AbbVie

    • Industry Developments and Future Opportunities: 

    Various initiatives by key players operating in the prostate cancer therapeutics market are listed below:

    1. In March 2022, the US FDA approved Novartis’s Pluvicto (lutetium Lu 177 vipivotide tetraxetan) for treating adult patients with a type of advanced prostate cancer called prostate-specific membrane antigen-positive metastatic castration-resistant prostate cancer (PSMA-positive mCRPC).
    2. In April 2023, the FDA granted Lantheus Holdings Inc and POINT Biopharma Global Inc fast track designation for 177Lu-PNT2002 for treating metastatic castration-resistant prostate cancer (mCRPC). PNT2002 is an innovative PSMA-targeted 177Lu-based radiopharmaceutical therapy that combines PSMA-targeted ligand, PSMA-I&T, and beta-emitting radioisotope no-carrier-added 177Lu for treating mCRPC.

    Competitive Landscape and Key Companies:

    Astella Pharma Inc, Johnson & Johnson Services Inc, Eli Lilly and Company, Bayer AG, Sanofi, Merck KGaA, AstraZeneca, Novartis AG, AbbVie, and Bristol Myers Squibb are among the prominent players operating in the prostate cancer therapeutics market. These market players focus on new product launches and geographic expansions to fulfill the growing consumer demand worldwide and increase their product range in specialty portfolios. Their global presence allows them to serve a large base of customers, subsequently facilitating market expansion.